Protocol Ledger

NCT06738979 · Phase III · COMPLETED

A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

Interventional Phase III clinical trial protocol NCT06738979 sponsored by Chia Tai Tianqing Pharmaceutical Group Co in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-20 Enrollment: 408 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06738979
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)408 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06738979
Protocol FieldVerified Registry Value
NCT IdentifierNCT06738979
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Co
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment408 participants (ACTUAL)
Registered Start Date2025-03-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI